HOME >> MEDICINE >> NEWS
Passing stop sign cures gene disease

awbacks. The body absorbs it poorly, so it must be injected or inhaled. And inhaling is fine for cystic fibrosis, but of little use for conditions such as muscular dystrophy. The antibiotic can also cause rare but serious side effects such as hearing loss and kidney damage.

That's where PTC124 comes in: it was designed from the start to have similar properties to gentamicin but to be safer and more easily absorbed. "We are really in a different situation now, where we are trying to identify drugs based on how they should act," says Langdon Miller, chief medical officer of PTC Therapeutics in New Jersey.

The drug was screened out of a pool of 175,000 synthetic molecules. Pre-clinical tests so far indicate that it is more potent than gentamicin and seems to have very low toxicity. "This could have very far-reaching effects," claims David Bedwell, a microbiologist at the University of Alabama in Birmingham, who has tested the compound in his lab and is collaborating with the company.

In mice with muscular dystrophy the drug restores expression of the dystrophin protein found on the surface of muscle cells. Tests suggest the muscles regain some of their normal characteristics. Tests on mice with cystic fibrosis also suggest PTC124 restores production of functional CFTR.

All the results remain unpublished, though researchers working with the company say they hope to publish as soon as intellectual property issues are resolved. Miller says the company hopes to start clinical trials with healthy volunteers as early as next year.

But a premature stop mutation will not always be the cause of a particular genetic disease. So even if PTC124 or gentamicin make it to the market for treating genetic diseases, they will not be a magical cure for everyone.


'"/>

Contact: Claire Bowles
claire.bowles@rbi.co.uk
44-207-331-2751
New Scientist
15-Oct-2003


Page: 1 2

Related medicine news :

1. Procedure cures atrial fibrillation
2. First UK cases of previously rare disease reported in gay men
3. Uric acid and heart disease
4. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
5. Risky surgery not always necessary to treat cervical disease
6. Stanford patient is first to test new treatment for peripheral arterial disease
7. Community care tops medical care at preventing heart disease in black Americans
8. Neuronal death and processing of Tau protein in Alzheimers disease
9. Researchers say breast cancer in Africa may provide clues to the disease in African-Americans
10. Reducing hostility in young coronary artery disease patients is important piece of rehabilitation
11. Study finds direct association between cardiovascular disease and periodontal bacteria

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Passing stop sign cures gene disease

(Date:7/6/2015)... ... 06, 2015 , ... University of Pittsburgh Cancer Institute (UPCI) scientists ... to reflect newly available tests that better incorporate personalized medicine into diagnosing the condition. ... cancer tests is published in the July issue of the scientific journal Thyroid ...
(Date:7/6/2015)... Branford, Connecticut (PRWEB) , ... July 06, 2015 ... ... Aesthetic Medical Practice & Medical Spa industries, announces the return of its complimentary ... the Acara team of aesthetic medical business leaders creates success for their clients ...
(Date:7/6/2015)... BC (PRWEB) , ... July 06, 2015 , ... Olive ... received the UBC 2014-2015 Post Graduate Teaching Award on behalf of the department of ... is a very exciting field to be practicing in. The technology is changing so ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... newly-diagnosed cancer patients, caregivers and medical professionals to chat with the CHN patient ... cancer. , “Receiving a cancer diagnosis is often the most traumatic experience of ...
(Date:7/6/2015)... ... , ... MD Now, the leading and fastest-growing urgent care provider in Florida, ... will serve residents and visitors in the Cutler Bay area, giving them convenient access ... location, the new facility will be the fourth to serve Miami-Dade County. Located at ...
Breaking Medicine News(10 mins):Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 2Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 3Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 4Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 5Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 3Health News:Olive Fertility Centre Physician Honoured for Teaching 2Health News:Cancer Hope Network Launches Upgraded Website to Support Cancer Patients, Caregivers 2Health News:MD Now Urgent Care Opens its Fourth Miami-Dade County Facility in Cutler Bay 2Health News:MD Now Urgent Care Opens its Fourth Miami-Dade County Facility in Cutler Bay 3
(Date:7/6/2015)... , July 6, 2015 Moerae Matrix, ... novel therapeutics that target inflammation and fibrosis, today ... M.D., PhD, as Chief Medical Officer. ... development strategy and programs, which include a pipeline ... and fibrotic conditions.  Bill is an accomplished strategist ...
(Date:7/6/2015)... , July 6, 2015 Celtaxsys, Inc., a ... including those with rare and orphan inflammatory disease indications, ... U.S. Food and Drug Administration (FDA) to begin a ... acebilustat (CTX-4430), in adult CF patients in the US. ... Europe will be filed soon after. ...
(Date:7/6/2015)... SUNNYVALE, Calif. , July 6, 2015   ... will report financial results for its 2015 second quarter ... after the close of the market. The ... Pacific Time on Thursday, July 23, 2015, to discuss ... Cepheid,s website at http://ir.cepheid.com at least 15 ...
Breaking Medicine Technology:Moerae Matrix, Inc. (Moerae) Appoints Bill Bradford, M.D., PhD, as Chief Medical Officer 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3
Cached News: